Results 161 to 170 of about 27,465 (289)

Differential segment‐specific signalling pathways for guanylate cyclase C‐activated anion secretion in murine ileocolon

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Guanylate cyclase‐C (GC‐C) is the receptor for endogenous (uro)guanylin peptides, bacterial toxins and pharmacological analogues. Receptor activation leads to intestinal fluid loss, but also activates an antiproliferative pathway and is a promising target in colorectal cancer therapy.
Renjie Xiu, Johannes Reiner, Franz Hofmann, Azam Salari, Ursula Seidler   +4 more
wiley   +1 more source

Genetic Determinants Associated With the Biofilm Formation Impairment in Pseudomonas aeruginosa Clinical Isolates. [PDF]

Microbiologyopen
Vvedenskii AV, Ivkina AS, Konanov DN, Savinova TA, Fedorova LS, Ilina EN.   +5 more
europepmc   +1 more source

Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials

British Journal of Pharmacology, EarlyView.
Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen, Declan P. McKernan, John P. Kelly   +2 more
wiley   +1 more source

Divergent viral phosphodiesterases for immune signaling evasion. [PDF]

Cell Host Microbe
Doherty EE, Nomburg J, Adler BA, Lopez S, Hsieh K, Price N, Blount N, Doudna JA.   +7 more
europepmc   +1 more source

Epigenetic mechanisms and therapeutic innovations in chronic pain‐associated neuropsychiatric co‐morbidities

British Journal of Pharmacology, EarlyView.
Abstract Chronic pain, marked by nociceptive sensitization and maladaptive neuroplasticity, affects 30% of the global population with escalating socioeconomic burdens. Epidemiological data show a 2‐3‐fold increase in neuropsychiatric co‐morbidities among individuals with chronic pain, where epigenetic dysregulation serves as a key mechanism linking ...
Kai Zhang, Sijia Zhu, Na Xing, Zhen Zhou, Jiayi Chen, Tianen Si, Mingrui Li, Lin Jia, Yousef Rastegar‐Kashkooli, Tom J. Wang, Wei Zhu, Jing Li, Chao Jiang, Junmin Wang, Moxin Wu, Xiaoping Yin, Weidong Zang, Jian Wang, Songxue Su   +18 more
wiley   +1 more source

Covalent Binding of the Boronic Acid-Based Inhibitor GSK4394835A to Phosphodiesterase 3B, a Drug Target for Cardiovascular Disease. [PDF]

J Med Chem
Eaton SA, Christianson DW.
europepmc   +1 more source

A role for epithelium‐derived 6‐nitrodopamine on human ureter contractility

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose To investigate the basal release of 6‐nitrodopamine (6‐ND) from human isolated ureter and the role of this novel catecholamine in the ureter contractility. Experimental Approach Ureters from 67 brain‐dead organ donors (40 males and 27 females) were used during kidney transplantation procedures.
Wilmar Azal Neto, Denis Lima Oliveira, José Britto‐Júnior, Alex Henrique Miller, Flaviano Lorenzon, Felipe Fernandes Jacintho, Valéria Barbosa de Souza, Fernanda Viviane Mariano, André Almeida Schenka, Fabiola Zakia Mónica, Adriano Fregonesi, Edson Antunes, Gilberto De Nucci   +12 more
wiley   +1 more source

"Cyclic nucleotides in plants: from obscure messengers to central regulators". [PDF]

Front Plant Sci
Świeżawska-Boniecka B, Szmidt-Jaworska A.   +1 more
europepmc   +1 more source

Targeting Genome Maintenance Defects of Cancers Using Chain‐Terminating Nucleoside Analogs

Cancer Science, EarlyView.
Nucleoside analogs interfere with DNA replication either by their chain‐terminating properties or by serving as DNA damage on the template. The genome maintenance pathways required to maintain cellular tolerance to each nucleoside analog vary depending on the drug.
Ryotaro Kawasumi, Rubaiat E. Tabassum, Kouji Hirota   +2 more
wiley   +1 more source

The dopamine paradox in glioblastoma oncology: methylxanthine therapy against nicotine-driven pathogenesis. [PDF]

Ann Med Surg (Lond)
Mursaleen M, Tahir M, Suleman MU, Tabassum SN, Khalil U.   +4 more
europepmc   +1 more source